Search results for "bodies"

showing 10 items of 2217 documents

Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study

2021

Background: Ligelizumab, a next-generation, humanized anti-immunoglobulin E (IgE) monoclonal antibody is in development as a treatment for patients with chronic spontaneous urticaria, whose symptoms are inadequately controlled with standard-of-care therapy. Objective: To evaluate the long-term safety and re-treatment efficacy of ligelizumab 240 mg in patients who completed the core study and extension study. Methods: This open-label, single-arm, long-term Phase 2b extension study was designed to assess patients who were previously administered various doses of ligelizumab, omalizumab or placebo in the Phase 2b, dose-finding core study and who presented with active disease after Week 32. In …

medicine.medical_specialtyUrticariaImmunologyLigelizumab610OmalizumabOmalizumabImmunoglobulin EPlaceboAntibodies Monoclonal HumanizedInternal medicineActive diseasemedicineImmunology and AllergyHumansIn patientChronic UrticariaAdverse effectbiologybusiness.industryExtension studyChronic spontaneous urticariaTreatment OutcomeLigelizumabbiology.proteinIgEbusiness600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drug
researchProduct

Thrombotic thrombocytopenic purpura (TTP) leading to pseudotumour's autoimmune pancreatitis (AIP): A case report

2012

International audience; Introduction: Autoimmune pancreatitis is an idiopathic inflammatory disease that produces pancreatic masses and ductal strictures. This benign disease can be associated with extrapancreatic manifestations including cholangitis, sialadenitis, inflammatory bowel disease or retroperitoneal fibrosis, mediastinal adenopathy, interstitial nephritis mainly due to immunoglobulin G4 (Ig G4), and occasional association with other auto-immune diseases. Observation: We report a 57-year-old woman who developed thrombotic thrombocytopenic purpura (UP) and pseudo-tumour's seronegative autoimmune pancreatitis (ATP) type 1. The patient was initially treated with pulse corticosteroids…

medicine.medical_specialtyVON-WILLEBRAND-FACTOREndocrinology Diabetes and Metabolismmedicine.medical_treatmentInterstitial nephritisAnti-Inflammatory AgentsThrombotic thrombocytopenic purpuraRetroperitoneal fibrosisGastroenterologyInflammatory bowel diseaseDISEASEAutoimmune DiseasesAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineThrombotic thrombocytopenic purpuraInternal medicine[SDV.IDA]Life Sciences [q-bio]/Food engineeringmedicineHumans[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process EngineeringSYSTEMIC-LUPUS-ERYTHEMATOSUSAutoimmune pancreatitisAutoimmune pancreatitisPurpura Thrombotic ThrombocytopenicHepatologybusiness.industryENTITYGastroenterologyMiddle Agedmedicine.diseaseSialadenitis3. Good healthPancreatitis030220 oncology & carcinogenesisImmunologyFemale030211 gastroenterology & hepatologyRituximabPlasmapheresismedicine.symptombusinessRituximabmedicine.drug
researchProduct

Weight loss in Alzheimer’s disease, vascular dementia and dementia with Lewy bodies: Impact on mortality and hospitalization by dementia subtype

2021

Objectives Loss of weight is associated with cognitive decline as well as several adverse outcomes in dementia. The aim of this study was to assess whether weight loss is associated with mortality and hospitalization in dementia subtypes. Methods A cohort of 11,607 patients with dementia in Alzheimer's disease (AD), vascular dementia (VD), or dementia with Lewy bodies (DLB) was assembled from a large dementia care health records database in Southeast London. A natural language processing algorithm was developed to established whether loss of weight was recorded around the time of dementia diagnosis. Cox proportional hazard models were applied to examine the associations of reported weight l…

medicine.medical_specialtyWeight lossInternal medicinemental disordersmedicineDementiaCognitive declineVascular dementiaImpact on mortality and hospitalization by dementia subtype.- International journal of geriatric psychiatry 2021 [Soysal P. Tan S. G. Rogowska M. Jawad S. Smith L. Veronese N. Tsiptsios D. Tsamakis K. Stewart R. Mueller C. -Weight loss in Alzheimer-s disease vascular dementia and dementia with Lewy bodies]Dementia with Lewy bodiesbusiness.industryAlzheimer's disease dementia hospitalization Lewy bodies mortality weight lossHazard ratioAlzheimer's diseasemedicine.diseasemortalityConfidence intervalPsychiatry and Mental healthCohortGeriatrics and Gerontologymedicine.symptomweight lossbusinessLewy bodiesdementiahospitalization
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies : A Cohort Study

2018

Takotsubo syndrome (TTS) is an acute cardiac syndrome characterized by regional left ventricular dysfunction with a peculiar circumferential pattern, which typically results in apical ballooning. Evidence indicates a pivotal role of catecholamines in TTS, and researchers have discussed multiple hypotheses on the etiology, including multivessel coronary spasm, myocardial stunning, excessive transient ventricular afterload, and cardiac sympathetic overactivity with local noradrenaline spillover. Although central nervous system disorders, such as stroke and epilepsy, are known to trigger TTS, the incidence and clinical features of TTS in neurodegenerative disorders are poorly understood. Here,…

medicine.medical_specialtyamyotrophic lateral sclerosisParkinson's diseaseParkinson's diseaseCardiomyopathymultiple system atrophy030204 cardiovascular system & hematologylcsh:RC346-42903 medical and health sciences0302 clinical medicineAtrophyInternal medicineMedicinetakotsubo syndromeAmyotrophic lateral sclerosissympathetic nerveStrokelcsh:Neurology. Diseases of the nervous systemOriginal ResearchSynucleinopathiesbusiness.industryDementia with Lewy bodiesmedicine.diseaseNeurologyEtiologyCardiologyParkinson’s diseasenoradrenalineNeurology (clinical)synucleinopathybusinessdementia with Lewy bodies030217 neurology & neurosurgeryFrontiers in Neurology
researchProduct

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

2019

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and Europea…

medicine.medical_specialtyantisynthetase antibodies; antisynthetase syndrome; arthritis; interstitial lung disease; myositisantisynthetase syndrome; antisynthetase antibodies; arthritis; myositis; interstitial lung diseaseMedizinArthritislcsh:MedicineAntisynthetase syndromeInterstitial lung diseaseAntisynthetase syndromeArticleNO03 medical and health sciences0302 clinical medicineInternal medicinemedicineantisynthetase antibodiesantisynthetase antibodies antisynthetase syndrome arthritis interstitial lung disease myositisddc:610Myositis030203 arthritis & rheumatologyinterstitial lung diseaseAntisynthetase antibodiesbiologyMyositisbusiness.industryArthritislcsh:RInterstitial lung diseaseAutoantibodyGeneral Medicinemedicine.diseasearthriti030228 respiratory systemarthritisTime courseCohortbiology.proteinAntibodyantisynthetase syndromebusinessantisynthetase antibodiemyositis
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

The history of meniscal-surgery

2000

In comparison with other operative procedures, the history of meniscal-surgery offers some particular differences. Over a long period of time injuries of the semilunar-cartilages of the knee-joint were not generally recognised. In the 18th century only was the clinical picture roughly outlined. There is evidence, that parts of the meniscus were removed much earlier than we have historic proof of. These meniscal fragments were generally mistaken for "loose bodies" in the joints, not knowing the exact etiology. Operative interference with joints was afflicted with a very high incidence of infections and thus complications. Due to this reliable standards of sterility were imperative to obtain …

medicine.medical_specialtybusiness.industrySemilunar CartilagesLong periodJoint Loose BodiesOrthopedic surgeryTotal removalMedicineOrthopedics and Sports MedicineHigh incidencebusinessOrthopedic ProceduresSurgeryDer Orthopäde
researchProduct

Nachweis von SLA/LP-Autoantikörpern bei Patienten mit primär biliärer Zirrhose als Marker für eine sekundäre autoimmune Hepatitis (Overlapsyndrom)

2001

BACKGROUND AND OBJECTIVE The aim of this study was to evaluate whether the presence of SLA/LP-autoantibodies in PBC-patients gives evidence for a secondary AIH, also called AIH/PBC-overlap-syndrome. PATIENTS AND METHODS Out of 233 consecutive patients with PBC who had been followed between October 1980 and April 2000, we evaluated the data of anti-SLA/LP-positive patients and compared them to patients with an anti-SLA/LP-negative AIH/PBC overlap syndrome as well as to patients with a classical course of AIH and PBC. RESULTS In total we could identify nine PBC patients with anti-SLA/LP antibodies (six women/three men) or 3.9% of the study population, Anti-SLA/LP-positive PBC patients were sl…

medicine.medical_specialtybusiness.industryfungiAutoantibodyOverlap syndromeGeneral MedicineAutoimmune hepatitismedicine.diseasedigestive systemGastroenterologydigestive system diseasesDiscontinuationPrimary biliary cirrhosisCholestasisInternal medicineMedicinePopulation studyskin and connective tissue diseasesbusinessAnti-SSA/Ro autoantibodiesDMW - Deutsche Medizinische Wochenschrift
researchProduct

Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study

2017

Background: The measurement of TSH receptor (TSHR) antibodies is warranted for diagnosis of Graves’ disease (GD). Objective: The performance, detection sensitivity, and specificity of 6 TSHR immunoassays were compared. Methods: Two bioassays and 4 binding assays (Kronus, Immulite, Kryptor, Dynex) were compared in a dilution study performed in patients with autoimmune thyroid disease. Both bioassays were compared to 2 binding assays using stimulatory (M22) and blocking (K1–70) monoclonal antibody (MAb) mixtures. Results: Thirty samples from stimulatory (TSAb)-positive/blocking (TBAb)-negative patients with GD were diluted serially and measured in all assays. Samples were positive until dilut…

medicine.medical_specialtyendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismMonoclonal antibodyThyroiditis03 medical and health sciences0302 clinical medicineInternal medicinemedicineBioassaySample dilutionReceptorTranslational Thyroidology / Original Paperbiologybusiness.industrymedicine.diseaseMolecular biologyAnti-thyroid autoantibodiesEndocrinologyMulticenter study030220 oncology & carcinogenesisbiology.proteinAntibodybusinessEuropean Thyroid Journal
researchProduct